Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CCCC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cemsidomide | Multiple Myeloma | Phase 2 · NCT07284758 | Recruiting |
| Tagarafdeg (CFT1946) | Solid Tumors | Phase 1 · NCT05668585 | Completed |
| Sendegobresib (CFT8634) | Synovial Sarcoma | Phase 1 · NCT05355753 | Terminated |
Also used in these trials (approved or third-party drugs, not CCCC's own candidates): Dexamethasone, Cetuximab, Elranatamab, Trametinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CCCC holds $274.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.8M/quarter from operations, an estimated runway of 59.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 24 · Moderate
We believe that these funds will be sufficient to fund our planned operating expenses to the end of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CCCC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Sirenia Capital Management LP | Institution (13G, 5%+) | 23,505,000 | 17.90% | 2026-03-31 |
| Lynx1 Capital Management LP | 5%+ holder (13G) | 15,423,691 | 11.75% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 13,654,272 | 10.40% | 2026-09-30 |
| Soleus Capital Master Fund, L.P. | Institution (13G, 5%+) | 10,361,860 | 7.89% | 2025-12-31 |
| Squadron Master Fund LP | 5%+ holder (13G) | 9,718,683 | 7.40% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 7,678,906 | 5.85% | 2026-06-30 |
| Andrew Hirsch President & CEO, Director |
Insider | 1,074,934 | 0.82% | 2026-02-13 |
| Leonard Reyno Chief Medical Officer |
Insider | 372,406 | 0.28% | 2026-07-10 |
| Kenneth Carl Anderson Director · +97,500 options |
Insider | 361,897 | 0.28% | 2026-10-01 |
| Kendra Adams Chief Financial Officer |
Insider | 337,150 | 0.26% | 2026-11-12 |
| Paige Mahaney Chief Scientific Officer |
Insider | 336,910 | 0.26% | 2026-02-13 |
| Kelly Schick Chief People Officer |
Insider | 299,881 | 0.23% | 2026-02-13 |
Share count 131,317,488 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CCCC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →